Julie Alexandre et al., J Biotechnol Biomater 2017, 7:1(Suppl)
http://dx.doi.org/10.4172/2155-952X.C1.071

Novel human indoleamine 2,3-dioxygenase inhibitors form a long-lived complex with the enzyme

Julie Alexandre, Michael Swan, Mike Latchem, Dean Boyall, John Pollard, Stuart Hughes and James Westcott
Vertex Pharmaceuticals Ltd., UK

Human indoleamine 2,3-dioxygenase 1 (IDO) catalyzes the conversion of L-tryptophan (L-Trp) to N-formylkynurenine through a heme and O_2-dependent oxidation process. IDO is recognized as a central regulator of immune responses in a broad variety of physiological and pathological settings and is thus considered an attractive therapeutic target. In search of novel IDO inhibitors, we

Notes: